Literature DB >> 16056149

Age at onset of schizophrenia: interaction between brain-derived neurotrophic factor and dopamine D3 receptor gene variants.

David Gourion1, Celine Goldberger, Sophie Leroy, Marie-Chantal Bourdel, Jean-Pierre Olié, Marie-Odile Krebs.   

Abstract

One of the main features of schizophrenia is its age at onset in early adulthood. Dopaminergic dysregulation is the most documented neurobiological factor that may be involved in triggering schizophrenia. Recent findings on neurodevelopmental processes show that the brain-derived neurotrophic factor plays a critical role in the development of mesolimbic dopaminergic-related systems and regulates the expression of dopamine D3 receptors. In this study, we examine whether an interaction between dopamine D3 receptors and brain-derived neurotrophic factor gene variants influences age at onset in patients with schizophrenia. Our findings show that this gene-gene interaction was significantly associated with an earlier emergence of psychosis by 3 years.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16056149     DOI: 10.1097/01.wnr.0000175245.58708.6b

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  14 in total

1.  Interaction between catechol-O-methyltransferase (COMT) Val108/158Met and brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in age at onset and clinical symptoms in schizophrenia.

Authors:  S Numata; S Ueno; J Iga; K Yamauchi; S Hongwei; S Kinouchi; S Shibuya-Tayoshi; S Tayoshi; H Aki; S Sumitani; M Itakura; T Ohmori
Journal:  J Neural Transm (Vienna)       Date:  2006-08-08       Impact factor: 3.575

Review 2.  The BDNF gene Val66Met polymorphism as a modifier of psychiatric disorder susceptibility: progress and controversy.

Authors:  M Notaras; R Hill; M van den Buuse
Journal:  Mol Psychiatry       Date:  2015-03-31       Impact factor: 15.992

3.  Brain-Derived Neurotrophic Factor Gene Val66Met Polymorphism and Risk of Schizophrenia: A Meta-analysis of Case-Control Studies.

Authors:  Majid Kheirollahi; Elahe Kazemi; Saeideh Ashouri
Journal:  Cell Mol Neurobiol       Date:  2015-07-02       Impact factor: 5.046

4.  Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study.

Authors:  Mingqing Xu; Sheng Li; Qinghe Xing; Rui Gao; Guoyin Feng; Zhiguang Lin; David St Clair; Lin He
Journal:  Eur J Hum Genet       Date:  2010-01-20       Impact factor: 4.246

5.  BDNF Val66Met variant and age of onset in schizophrenia.

Authors:  Helen M Chao; Hung-Teh Kao; Barbara Porton
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-06-05       Impact factor: 3.568

6.  Schizophrenia: from brain morphology to psychopathology.

Authors:  Adriana Foster; Manzoor Usman; Edna Stirewalt; Peter Buckley
Journal:  Curr Psychiatry Rep       Date:  2007-08       Impact factor: 5.285

7.  BDNF Val66Met Genotype Interacts With a History of Simulated Stress Exposure to Regulate Sensorimotor Gating and Startle Reactivity.

Authors:  Michael J Notaras; Rachel A Hill; Joseph A Gogos; Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2017-05-01       Impact factor: 9.306

8.  Implication of the env gene of the human endogenous retrovirus W family in the expression of BDNF and DRD3 and development of recent-onset schizophrenia.

Authors:  WenJie Huang; Shan Li; YuanMing Hu; Honglian Yu; Feng Luo; Qi Zhang; Fan Zhu
Journal:  Schizophr Bull       Date:  2010-01-25       Impact factor: 9.306

Review 9.  NMDA receptor hypofunction for schizophrenia revisited: Perspectives from epigenetic mechanisms.

Authors:  Melissa A Snyder; Wen-Jun Gao
Journal:  Schizophr Res       Date:  2019-04-09       Impact factor: 4.939

Review 10.  Human Endogenous Retrovirus as Therapeutic Targets in Neurologic Disease.

Authors:  Karen Giménez-Orenga; Elisa Oltra
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.